Liothyronine (T3) vs Tirzepatide
FDA Approved vs FDA Approved
monitor Mechanism-based · 50% Both Liothyronine (T3) and Tirzepatide promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually.
Molecular Data
Liothyronine (T3) Tirzepatide
Weight 650.97 Da 4,813.55 Da
Half-life ~1 day ~5 days (120 hours)
Chain — 39 amino acids
Type Thyroid hormone (C15H12I3NO4) Dual GLP-1/GIP agonist
Key Benefits
Liothyronine (T3)
01 Direct and rapid increase in basal metabolic rate
02 Enhanced fat oxidation and lipolysis
03 Improved energy levels and reduction of hypothyroid fatigue
04 Faster-acting than T4 with effects noticeable within hours to days
05 Useful when peripheral T4-to-T3 conversion is impaired (illness, caloric deficit, stress)
06 Supports body temperature regulation and thermogenesis
07 Can improve cognitive clarity and reduce brain fog associated with low thyroid function
Tirzepatide
01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise
Dosing Protocols
Liothyronine (T3)
25-75 mcg/day (replacement) / 1-2x daily (oral)
Tirzepatide
2.5mg starting, titrate up to 5-15mg weekly / Once weekly (same day each week)
Weight loss initiation 2.5mg Once weekly x 4 weeks
Weight loss progression 5mg Once weekly
Weight loss optimization 7.5-10mg Once weekly
Maximum weight loss 12.5-15mg Once weekly
Diabetes management (mild) 5-7.5mg Once weekly
Diabetes management (severe) 10-15mg Once weekly
Side Effects
Liothyronine (T3)
Tachycardia and palpitations (increased heart rate, especially at higher doses)
Anxiety, nervousness, and irritability
Insomnia and disrupted sleep architecture
Increased sweating and heat intolerance
Tremor (fine hand tremor, similar to hyperthyroid presentation)
Increased appetite despite accelerated metabolism
Loose stools or increased bowel frequency
Tirzepatide
Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings
Contraindications
Untreated adrenal insufficiency (must correct cortisol deficiency before starting T3)
Acute myocardial infarction or unstable angina
Thyrotoxicosis or untreated hyperthyroidism
Known hypersensitivity to liothyronine or any tablet excipients
Uncorrected adrenal cortical insufficiency (risk of adrenal crisis)
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Liothyronine (T3) Tirzepatide
Status FDA Approved FDA Approved
References 5 studies 8 studies
Latest September 2023 2025-12
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.